You are here:

MS in the media - 18 August 2017

Published on

12 - 18 August 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Armed forces at higher risk of dying from MS

A study looking at the death certificates of nearly 3.7million men over 31 years found that people who had served in the armed forces had a higher risk of being recorded as dying from MS than people in other occupations.  The research is unable to suggest why this might be the case.

Source: Daily Telegraph

MS Trust link: Life expectancy

Sticking with disease modifying drugs

A recently published report of research from a conference in April discusses why people with MS stop taking injected disease modifying drugs.  After two years, more than a third were no longer on the drug on which they started. This has implications for treatment as the drugs may not have be given enough time to become effective.

Source: MedPage Today

MS Trust link: MS Decisions - a guide to treatments for relapsing MS

Older MS drugs and increased cancer risk

A Sicilian study found that people treated with some of the older drugs used for MS - azathioprine, cyclophosphamide and mitoxantrone - had an increased risk of cancer. The problems associated with these drugs have been known for some time and they have not been widely used for MS in the UK.

Source: Medpage Today

MS Trust link: MS Decisions - a guide to treatments for relapsing MS

Gut bacteria

A common bacterium in gut (Prevotella histicola) prevented an MS-like conditions from developing in animals. Other studies have shown lower levels of P. histicola in people with MS and an increase when people are treated with disease modifying drugs.  A separate study found that people with secondary progressive MS have more antibodies to the Helicobacter pylori bacterium than people with relapsing remitting MS.

Source: MS News Today
Source: MS News Today

MS Trust link: MS research updates

Cladribine and quality of life

Researchers in London have published previously unavailable data from an older trial of cladribine to show that it improves quality of life for people with MS. Cladribine is currently going through the licensing process with the EMA (European Medicines Agency).

Source: News Medical

MS Trust link: European licence recommended for cladribine (Mavenclad)

Print this page